CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 14 enrolled
Drug / intervention
OTL38 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02645409
NCT02645409N/ACompleted

Intraoperative Folate Targeted Fluorescence in Renal Cell Carcinoma

Chandru Sundaram·interventional·Posted Jan 1, 2016·Updated Feb 25, 2020

In Brief

A clinical study evaluating OTL38 and Intraoperative fluorescence imaging system for Renal Cell Carcinoma. Completed, enrolled 14 participants across 2 sites.

Detailed Summary

Primary • To explore the use of OTL38 and fluorescence imaging to detect RCC in partial nephrectomy at the margins of resection, and in lymph node(s) or other metastases during radical nephrectomy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedJan 1, 2016
Enrollment StartDec 29, 2015
Primary CompletionMar 20, 2018
Study CompletionApr 2, 2019
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 10.5 years ago

Interventions

OTL38drug

OTL38 is a folate analog conjugated with a fluorescent dye that emits light in the near infrared spectrum. This longer wavelength allows for deeper penetration of the fluorescent light through tissues with the potential to better image tumors beneath adipose tissue or deeper into organ parenchyma.

Intraoperative fluorescence imaging systemdevice